Sublingual Buprenorphine for Chronic Pain
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by National Institute on Drug Abuse (NIDA).
Recruitment status was Not yet recruiting
Recruitment status was Not yet recruiting
Sponsor:
Collaborator:
Beth Israel Medical Center
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00612287
First received: February 6, 2008
Last updated: April 6, 2009
Last verified: April 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to develop and pilot test clinical guidelines for the use of buprenorphine for the treatment chronic pain among patients with substance abuse histories. Buprenorphine, an opioid medication, holds promise as a treatment of chronic pain because, compared to most other opioid analgesics, it has a high safety profile, a low level of physical dependence, and mild withdrawal symptoms on cessation. Moreover there are promising reports from Europe of its use as a skin patch to treat chronic pain as well as clinical reports in the U.S. that it may be effective when used sublingually (placed under the tongue). This study will test the sublingual formulation.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Pain |
Drug: buprenorphine |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Sublingual Buprenorphine for Chronic Pain in Patients at Risk for Drug Abuse |
Resource links provided by NLM:
Further study details as provided by National Institute on Drug Abuse (NIDA):
Primary Outcome Measures:
- Pain severity [ Time Frame: 1, 2, 3, 4, 5 & 6 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Pain behaviors, psychiatric distress, drug use, side effects [ Time Frame: Months 1 through 6 ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 40 |
| Study Start Date: | April 2009 |
| Estimated Study Completion Date: | August 2009 |
| Estimated Primary Completion Date: | May 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: A |
Drug: buprenorphine
Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
Other Name: Suboxone®
|
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Undergoing treatment for moderate-severe chronic pain for at least six months at either an ambulatory practice of the Department of Pain and Palliative Medicine Beth Israel Medical Center in New York City or the the Peter Kruger Clinic at the same institution.
Either
- On opioid therapy (any dose) and observed to have had at least four of the aberrant drug-related behaviors described in (Passik et al. Clin J Pain; 22(2):173-81 2006) during the past six months, or
- Considered a candidate for long-term therapy by the pain specialist and a history of a substance use disorder, as determined by DSM-IV criteria, but no longer meeting criteria for at least one year.
Age 18-70
Exclusion Criteria:
- Meets DSM-IV criteria for current opioid dependence or other substance use disorder including alcohol abuse.
- Currently being treated for opioid dependence with methadone.
- Currently maintained on naltrexone (e.g., for alcohol dependence).
- Taking benzodiazepines on a daily basis.
- A history of moderate-severe cardiopulmonary disease or symptoms or signs consistent with moderate-severe cardiopulmonary disease.
- Elevated liver function test (LFT) results (> 2.5 above normal).
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00612287
Contacts
| Contact: Russell K Portenoy, MD | 212-844-1505 | Rportenoy@bethisrael.org |
Locations
| United States, New York | |
| Beth Israel Medical Center | Not yet recruiting |
| New York, New York, United States, 10003 | |
| Principal Investigator: Russell K Portenoy, MD | |
| Beth Israel Medical Center | Not yet recruiting |
| New York, New York, United States, 10003 | |
Sponsors and Collaborators
Beth Israel Medical Center
Investigators
| Principal Investigator: | Andrew Rosenblum, PhD | NDRI |
More Information
No publications provided
| Responsible Party: | Andrew Rosenblum, PhD, National Development and Research Institutes |
| ClinicalTrials.gov Identifier: | NCT00612287 History of Changes |
| Other Study ID Numbers: | R21 DA022675 |
| Study First Received: | February 6, 2008 |
| Last Updated: | April 6, 2009 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by National Institute on Drug Abuse (NIDA):
|
Pain Chronic pain Buprenorphine Drug addiction |
Additional relevant MeSH terms:
|
Buprenorphine Analgesics, Opioid Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Central Nervous System Depressants Narcotic Antagonists Narcotics |
ClinicalTrials.gov processed this record on June 17, 2013